Psilocybin therapy of psychiatric disorders is not hampered by hERG potassium channel-mediated cardiotoxicity
Hackl, B., Todt, H., Kubista, H., Hilber, K., Koenig, X.
This brief report details that a high dose of psilocin (the active metabolite of psilocybin) doesn't cause adverse heart-related issues (e.g. QT interval prolongation). The route, via hERG channel blockage, is not activated by psilocin.
Abstract
Psilocybin, a hallucinogen contained in magic mushrooms, holds great promise for the treatment of various psychiatric disorders, and early clinical trials are encouraging. Adverse cardiac events after intake of high doses of psilocybin, and a trial reporting QT interval prolongation in the electrocardiogram, attributed to the drugs main metabolite psilocin, gave rise to safety concerns. Here we show that clinical concentrations of psilocin do not cause significant hERG potassium channel inhibition, a major risk factor for adverse cardiac events. We conclude that hERG channel blockage by psilocin is not liable for psilocybin- associated cardiotoxic effects.